KAT2B is able to inhibit tumorigenicity in gastric cancer cells not only in vivo but in vitro, prevent gastric cancer cells from entering S phase from G1 stage and its decrease in expression linked with poor clinical prognosis of intestinal gastric cancer [15]. Here, KAT2B is linked to gastric cancer.